Bristol-Myers Squibb Co. (BMY)

48.16
NYSE : Health Technology
Prev Close 48.92
Day Low/High 48.15 / 49.06
52 Wk Low/High 44.30 / 65.89
Avg Volume 18.54M
Exchange NYSE
Shares Outstanding 1.63B
Market Cap 79.86B
EPS 3.00
P/E Ratio 16.25
Div & Yield 1.64 (3.27%)
Jim Cramer: Bristol-Myers, Apple, and the Markets

Jim Cramer: Bristol-Myers, Apple, and the Markets

Jim Cramer's back and ready to tackle the Bristol-Myers Celgene deal, Apple and the markets.

Celgene (CELG) Alert: Johnson Fistel Investigates Proposed Sale Of Celgene Corporation; Are Celgene Shareholders Getting A Fair Deal?

Celgene (CELG) Alert: Johnson Fistel Investigates Proposed Sale Of Celgene Corporation; Are Celgene Shareholders Getting A Fair Deal?

SAN DIEGO, Jan. 3, 2019 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Celgene Corporation (NASDAQ: CELG) ("Celgene") breached their fiduciary duties in connection with the...

Bristol-Myers Squibb To Acquire Celgene To Create A Premier Innovative Biopharma Company

Bristol-Myers Squibb To Acquire Celgene To Create A Premier Innovative Biopharma Company

Bristol-Myers Squibb Company (NYSE:BMY) and Celgene Corporation (NASDAQ:CELG) today announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity...

Bristol-Myers Squibb Provides 2019 EPS Guidance

Bristol-Myers Squibb Provides 2019 EPS Guidance

Bristol-Myers Squibb (NYSE:BMY) today announced EPS guidance for full-year 2019.

Bristol-Myers Squibb Announces Offer From Taisho Pharmaceutical Holdings Co., Ltd To Purchase UPSA

Bristol-Myers Squibb Announces Offer From Taisho Pharmaceutical Holdings Co., Ltd To Purchase UPSA

Bristol-Myers Squibb Company (NYSE:BMY) today announced that Taisho Pharmaceutical Holdings Co.

Bristol-Myers Squibb And Boston Medical Center Announce Research Collaboration To Investigate Markers Of Immuno-Oncology Response And Resistance

Bristol-Myers Squibb And Boston Medical Center Announce Research Collaboration To Investigate Markers Of Immuno-Oncology Response And Resistance

Bristol-Myers Squibb Company (NYSE:BMY), and Boston Medical Center, a private, not-for-profit, academic medical center, today announced a multi-year joint research study to identify and analyze potential sensitivity and resistance markers in patients...

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Sprycel (dasatinib) For Pediatric Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Sprycel (dasatinib) For Pediatric Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Bristol-Myers Squibb Company (NYSE:BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the expanded approval of Sprycel (dasatinib), in combination with chemotherapy, to...

Jim Cramer: What to Buy in This Treacherous Market

Jim Cramer: What to Buy in This Treacherous Market

Look for the big-cap stocks that only come in on tough days -- and take advantage of their weakness at the open.

Bristol-Myers Squibb And Vedanta Biosciences Announce A New Clinical Collaboration To Evaluate OPDIVO (Nivolumab) And VE800 In Patients With Advanced Or Metastatic Cancers

Bristol-Myers Squibb And Vedanta Biosciences Announce A New Clinical Collaboration To Evaluate OPDIVO (Nivolumab) And VE800 In Patients With Advanced Or Metastatic Cancers

Bristol-Myers Squibb Company (NYSE:BMY) and Vedanta Biosciences today announced a clinical trial collaboration to evaluate Bristol-Myers Squibb's programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo in combination with Vedanta Biosciences' VE800,...

Bristol-Myers Squibb Announces Dividend Increase

Bristol-Myers Squibb Announces Dividend Increase

The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared an increase of 2.

Bristol-Myers Squibb To Announce Results For Fourth Quarter 2018 On January 24

Bristol-Myers Squibb To Announce Results For Fourth Quarter 2018 On January 24

Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the fourth quarter of 2018 on Thursday, January 24, 2019.

Bristol-Myers Squibb To Transfer $3.8 Billion In U.S. Pension Liabilities

Bristol-Myers Squibb To Transfer $3.8 Billion In U.S. Pension Liabilities

Bristol-Myers Squibb Company (NYSE: BMY) today announced it will transfer $3.8 billion of U.

Bristol-Myers Squibb To Highlight New Data From Broad Oncology Portfolio At The 60th American Society Of Hematology Annual Meeting

Bristol-Myers Squibb To Highlight New Data From Broad Oncology Portfolio At The 60th American Society Of Hematology Annual Meeting

Bristol-Myers Squibb Company (NYSE:BMY) today announced that 19 data presentations and publications, including two oral presentations, from Company-sponsored studies and collaborations evaluating Opdivo (nivolumab), Sprycel (dasatinib) and Empliciti...

Bristol-Myers Squibb To Take Part In Citi 2018 Global Healthcare Conference

Bristol-Myers Squibb To Take Part In Citi 2018 Global Healthcare Conference

Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Citi 2018 Global Healthcare Conference on Thursday, December 6, 2018 in New York.

Bristol-Myers Drops After Lung-Cancer Drug Study Fails

Bristol-Myers Drops After Lung-Cancer Drug Study Fails

Shares decline after the company says a lung-cancer study it had been working on failed.

Bristol-Myers Squibb Announces CheckMate -451 Study Did Not Meet Primary Endpoint Of Overall Survival With Opdivo Plus Yervoy Vs. Placebo As A Maintenance Therapy In Patients With Extensive-Stage Small Cell Lung Cancer After Completion Of First-Line Chemotherapy

Bristol-Myers Squibb Announces CheckMate -451 Study Did Not Meet Primary Endpoint Of Overall Survival With Opdivo Plus Yervoy Vs. Placebo As A Maintenance Therapy In Patients With Extensive-Stage Small Cell Lung Cancer After Completion Of First-Line Chemotherapy

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the Phase 3 CheckMate -451 study did not meet its primary endpoint of overall survival (OS) with Opdivo (nivolumab) 1 mg/kg in combination with Yervoy (ipilimumab) 3 mg/kg versus placebo as a...

Bristol-Myers Squibb Awards "Golden Tickets" For LabCentral To ReviveMed, Strand Therapeutics

Bristol-Myers Squibb Awards "Golden Tickets" For LabCentral To ReviveMed, Strand Therapeutics

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today announced that ReviveMed and Strand Therapeutics are the winners of Bristol-Myers...

Bristol-Myers Squibb To Take Part In Evercore ISI HealthCONx Conference

Bristol-Myers Squibb To Take Part In Evercore ISI HealthCONx Conference

Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Evercore ISI HealthCONx Conference on Tuesday, November 27, 2018, in Boston.

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval Of Opdivo® (nivolumab) Plus Low-Dose Yervoy® (ipilimumab) As First-Line Treatment For Patients With Intermediate- And Poor-Risk Advanced Renal Cell Carcinoma

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval Of Opdivo® (nivolumab) Plus Low-Dose Yervoy® (ipilimumab) As First-Line Treatment For Patients With Intermediate- And Poor-Risk Advanced Renal Cell Carcinoma

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion recommending approval of the Opdivo (nivolumab) plus low-dose Yervoy...

Drug Stocks Climb as Investors Digest Midterm Election Results

Drug Stocks Climb as Investors Digest Midterm Election Results

A split Congress is the best-case scenario for the drug industry, several analysts said.

Bristol-Myers Squibb To Take Part In Credit Suisse 2018 Health Care Conference

Bristol-Myers Squibb To Take Part In Credit Suisse 2018 Health Care Conference

Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Credit Suisse Annual Health Care Conference on Wednesday, November 14, 2018 in Scottsdale, AZ.

Bristol-Myers Squibb And Infinity Pharmaceuticals Announce A New Clinical Collaboration To Evaluate Opdivo (Nivolumab) In Combination With IPI-549 In Urothelial Cancer

Bristol-Myers Squibb And Infinity Pharmaceuticals Announce A New Clinical Collaboration To Evaluate Opdivo (Nivolumab) In Combination With IPI-549 In Urothelial Cancer

Bristol-Myers Squibb Company (NYSE: BMY) and Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced a clinical trial collaboration to evaluate Bristol-Myers Squibb's Opdivo in combination with Infinity's IPI-549 in patients with advanced urothelial...

A One-Two Punch to the Bears: Cramer's 'Mad Money' Recap (Thursday 11/1/18)

A One-Two Punch to the Bears: Cramer's 'Mad Money' Recap (Thursday 11/1/18)

Jim Cramer's been saying that that if the Fed or the president blink in their wars against inflation and China you could have an up day. That's what we got.

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Once the safest stocks in the book, the big-cap drug companies are now toxic.

Dow Closes 400 Points Higher as Wall Street Rebounds on Earnings

Dow Closes 400 Points Higher as Wall Street Rebounds on Earnings

The Dow Jones Industrial Average snaps back solidly Thursday after plunging more than 600 points in the previous session.

Bristol-Myers Beats Q3 Earnings, Boosts Full-Year Outlook on Solid Opdivo Sales

Bristol-Myers Beats Q3 Earnings, Boosts Full-Year Outlook on Solid Opdivo Sales

Bristol-Myers Squibb posts stronger-than-expected third-quarter earnings Thursday and boosts its full-year profit outlook.

TheStreet Quant Rating: C+ (Hold)